Reimbursement Review Reports

The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

For each drug, plasma product, or cell and gene therapy reviewed in the Drug Reimbursement Review process, there is an opportunity for patient groups and clinician groups to provide input and feedback. See Reimbursement Review Open Calls for Input and Feedback.

Brand Name Sort descending Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Alecensaro Alectinib Locally advanced or metastatic ALK+ NSCLC (first line) Reimburse with clinical criteria and/or conditions Complete
Alecensaro Alectinib Non-Small Cell Lung Cancer Do not reimburse Complete
Alecensaro alectinib ALK-positive NSCLC Active
Alimta Pemetrexed Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Reimburse with clinical criteria and/or conditions Complete
Aloxi (capsule) Palonosetron Chemotherapy-induced nausea and vomiting Withdrawn
Aloxi (capsule) Palonosetron hydrochloride Chemotherapy-induced nausea and vomiting Do not list Complete
Aloxi (injection) Palonosetron hydrochloride Chemotherapy-induced nausea and vomiting Do not list at the submitted price Complete
Alsitek masitinib mesylate Amyotrophic lateral sclerosis (ALS) Suspended
Altace HCT Ramipril/hydrochlorothiazide Hypertension Cancelled
Altace HCT Ramipril/hydrochlorothiazide Hypertension List Complete